JPWO2018235247A1 - 抗cd10抗体 - Google Patents
抗cd10抗体 Download PDFInfo
- Publication number
- JPWO2018235247A1 JPWO2018235247A1 JP2019524814A JP2019524814A JPWO2018235247A1 JP WO2018235247 A1 JPWO2018235247 A1 JP WO2018235247A1 JP 2019524814 A JP2019524814 A JP 2019524814A JP 2019524814 A JP2019524814 A JP 2019524814A JP WO2018235247 A1 JPWO2018235247 A1 JP WO2018235247A1
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- present
- amino acid
- cells
- antibody according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
- C12N5/12—Fused cells, e.g. hybridomas
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Public Health (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
HUH-7細胞(肝細胞癌、RIKEN Cell Bank(つくば市、茨城県)より入手)と、そのCD10トランスフェクタント(ヒトCD10分子をトランスフェクトしたHuH-7細胞)のそれぞれから回収した蛋白質をSDS-PADEで分離しPVDFメンブレンに転写した。メンブレンをPierce Fast Blocking Buffer (Pierce Biotechnology Inc.、東京)で処理した後、メンブレン2枚の一方はNEP1抗体を用いて、もう一方は抗CD10抗体(NCL-CD10, Leica Microsystems, 東京)を用いて室温で2時間反応させた。さらに、Anti-mouse HRP Labelled Polymerで室温30分反応させた。ECL Detection Kit (Amersham Biosciences) にて発色させ、撮影した。なお、上記NEP1抗体は、独立行政法人製品評価技術基盤機構 特許微生物寄託センター(千葉県木更津市かずさ鎌足2-5-8-122)に受託番号NITE BP-02489として国際寄託(受託日:2017年6月12日)されたハイブリドーマから産生されるマウス抗ヒトモノクローナル抗体である。
HuH-7細胞及びそのCD10トランスフェクタント(ヒトCD10分子をトランスフェクトしたHuH-7細胞)に対して、それぞれ1次抗体として、Control mouse Ig G1抗体(クローン名MOPC-21、TONBO bioscience サンディエゴ、カリフォルニア)、NEP1抗体、抗CD10抗体(クローン名B-E3、GEN-PROBE、サンディエゴ、カリフォルニア)、陽性コントロールの抗HLA-A,B,C抗体(クローン名W6/32, abcam ケンブリッジ、英国)を用いて、氷冷下で30分反応させた。2次抗体としてAlexa 647-conjugated rat anti-mouse IgGを用いて氷冷下で30分反応させた。BD LSRFortessa cell analyzer (BD Bioscience)で解析した。
NCI-H226細胞(悪性中皮腫細胞、American Type Culture Collection (ATCC)(マナサス、ヴァージニア)より入手)をBALB/c nuマウス1匹あたり、8×105個ずつ腹腔内へ注入した。9日後より、1匹あたりNEP1抗体100μg/ml、又はPBS(対照群)の投与を開始し、図3に示した間隔(2から3日おき)で投与し続けた。各群7匹よりスタートして生存曲線を求めた。
Claims (10)
- 受託番号NITE BP-02489のハイブリドーマにより産生される抗体の重鎖CDR1〜3及び軽鎖CDR1〜3のアミノ酸配列と同一のアミノ酸配列を有する、抗CD10抗体。
- 悪性腫瘍細胞の増殖を抑制する、請求項1に記載の抗CD10抗体。
- 受託番号NITE BP-02489のハイブリドーマにより産生される抗体の重鎖可変領域及び軽鎖可変領域のアミノ酸配列と同一のアミノ酸配列を有する、請求項1又は2に記載の抗CD10抗体。
- モノクローナル抗体である、請求項1〜3いずれかに記載の抗CD10抗体。
- 抗原結合性断片を含む、請求項1〜4いずれかに記載の抗CD10抗体。
- 請求項1〜5いずれかに記載の抗CD10抗体を含む、悪性腫瘍の治療用医薬組成物。
- 前記悪性腫瘍が、悪性中皮腫である、請求項6に記載の治療用医薬組成物。
- 請求項1〜5いずれかに記載の抗CD10抗体をコードするポリヌクレオチド又はベクター。
- 請求項1〜5いずれかに記載の抗CD10抗体をコードするポリヌクレオチドを含む、細胞。
- 受託番号NITE BP-02489のハイブリドーマである、請求項9に記載の細胞。
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/JP2017/023104 WO2018235247A1 (ja) | 2017-06-22 | 2017-06-22 | 抗cd10抗体 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPWO2018235247A1 true JPWO2018235247A1 (ja) | 2020-04-30 |
JP7002145B2 JP7002145B2 (ja) | 2022-02-21 |
Family
ID=64736034
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019524814A Active JP7002145B2 (ja) | 2017-06-22 | 2017-06-22 | 抗cd10抗体 |
Country Status (2)
Country | Link |
---|---|
JP (1) | JP7002145B2 (ja) |
WO (1) | WO2018235247A1 (ja) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022119932A1 (en) * | 2020-12-02 | 2022-06-09 | Agilent Technologies, Inc. | Anti-human cd10 antibodies for use in immunohistochemistry (ihc) protocols to diagnose cancer |
WO2024040194A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
CN116731181B (zh) * | 2023-07-17 | 2024-01-12 | 武汉爱博泰克生物科技有限公司 | 抗人cd10蛋白的兔单克隆抗体及其应用 |
-
2017
- 2017-06-22 WO PCT/JP2017/023104 patent/WO2018235247A1/ja active Application Filing
- 2017-06-22 JP JP2019524814A patent/JP7002145B2/ja active Active
Non-Patent Citations (2)
Title |
---|
BURNOR KJ ET AL.: "Expression of renal cell carcinoma-associated markers erythropoietin, CD10, and renal cell carcinoma", ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 2006, VOL. 130, NO. 6, PP. 823-827, vol. Abstract, JPN6017035346, ISSN: 0004546006 * |
MIZUTANI N. ET AL.: "Establishment of anti-mesothelioma monoclonal antibodies.", BMC RESEARCH NOTES, 2016, 9:324, vol. Abstract, JPN6017035348, ISSN: 0004546007 * |
Also Published As
Publication number | Publication date |
---|---|
WO2018235247A1 (ja) | 2018-12-27 |
JP7002145B2 (ja) | 2022-02-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6435381B2 (ja) | マトリクスメタロプロティナーゼ9に対する抗体 | |
JP5669732B2 (ja) | 抗axl抗体 | |
EP2236604B1 (en) | Anti-nr10 antibody and use thereof | |
BR112021002032A2 (pt) | construtos de anticorpos para cldn18.2 e cd3 | |
EP2354161B1 (en) | Anti-nr10 antibody, and use thereof | |
CN110407941B (zh) | Cd39的高亲和力抗体及其用途 | |
JP6675739B2 (ja) | 新規抗pad4抗体 | |
US11384139B2 (en) | Antibody targeting cell surface deposited complement protein C3d and use thereof | |
BR112020015736A2 (pt) | Anticorpo anti-b7-h4, fragmento de ligação a antígeno do mesmo e uso farmacêutico do mesmo | |
CA3193584A1 (en) | Nectin-4 antibodies and uses thereof | |
JP7002145B2 (ja) | 抗cd10抗体 | |
WO2019131769A1 (ja) | 新規抗pad4抗体 | |
WO2013147076A1 (ja) | インテグリンα8β1の機能を阻害する事による線維化の抑制 | |
WO2022237647A1 (zh) | 针对dll3的结合分子及其应用 | |
CN114761042A (zh) | Il-38特异性抗体 | |
CN114729013A (zh) | 抗cd22抗体及其用途 | |
AU2022246948A9 (en) | Il-38-specific antibodies |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20200601 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210706 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20211207 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20211220 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7002145 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |